NRIX Company Profile and Key Details

Q: Who are the executives of NRIX?

Mr. Howard A. Simon J.D., Esq., SPHRVice President of Operations & Corporation CounselDr. Christine RingGen. Counsel & Sec.Rita KwongSenior Accounting Mang.Mr. Howard A. Simon Esq., J.D., SPHRVice President of Operations & Corporation CounselMs. Stefani A. WolffChief Operating Officer & Executive Vice President of Product Devel.Dr. Gwenn M. Hansen Ph.D.Chief Scientific OfficerDr. Arthur T. Sands M.D., Ph.D.Chief Executive Officer, Pres & DirectorMr. Johannes Van HouteChief Financial OfficerDr. John Kuriyan Ph.D.Founder & Member of Scientific Advisory BoardDr. Michael Rapé Ph.D.Founder & Member of Scientific Advisory BoardProf. Arthur Weiss M.D., Ph.D.Founder & Member of Scientific Advisory BoardMr. Eric C. Schlezinger J.D.Chief People OfficerDr. Arthur Weiss M.D., Ph.D.Founder & Member of Scientific Advisory BoardDr. Michael T. Lotze F.A.C.S., M.D.Chief Cellular Therapy OfficerDr. Christine Ring J.D., Ph.D.Gen. Counsel & Sec.Dr. Jason Kantor Ph.D.Executive Vice President of Fin. & Bus. Strategy

NASDAQ : NRIX

Nurix Therapeutics

$19.30

0.67+3.60%

At Close 4:00 PM

59.19

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Nurix Therapeutics, Inc. (NRIX) stock surged +3.60%, trading at $19.30 on NASDAQ, up from the previous close of $18.63. The stock opened at $18.85, fluctuating between $18.64 and $19.31 in the recent session.

Stock Snapshot

18.63

Prev. Close

1.48B

Market Cap

18.64

Day Low

-6.5

P/E Ratio

-2.97

EPS (TTM)

-1.62

Cash Flow per Share

18.85

Open

76.88M

Number of Shares

19.31

Day High

98.01%

Free Float in %

3.07

Book Value

1.42M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jan 09, 2026	18.85	19.34	18.64	19.30	1.42M
Jan 08, 2026	19.86	19.92	18.35	18.63	1.35M
Jan 07, 2026	17.56	19.06	17.45	18.49	1.73M
Jan 06, 2026	17.39	17.76	16.98	17.43	1.68M
Jan 05, 2026	18.06	18.06	17.06	17.49	1.4M
Jan 02, 2026	19.00	19.03	17.86	18.06	1.47M
Dec 31, 2025	18.89	19.30	18.89	18.97	885.09K
Dec 30, 2025	19.24	19.47	18.78	19.02	1.03M
Dec 29, 2025	19.03	19.54	18.81	19.36	818.25K
Dec 26, 2025	19.35	19.37	18.97	19.30	763.84K
Dec 24, 2025	19.47	19.84	19.21	19.36	480.46K
Dec 23, 2025	19.11	19.63	19.11	19.29	882.85K
Dec 22, 2025	18.70	19.67	18.61	19.34	1.15M
Dec 19, 2025	18.00	18.87	17.91	18.52	4.61M
Dec 17, 2025	19.05	19.14	17.97	18.21	1.68M
Dec 16, 2025	19.06	19.25	18.32	18.84	1.71M
Dec 15, 2025	19.11	19.59	18.54	19.01	2.22M
Dec 12, 2025	19.07	19.68	19.06	19.07	1.55M
Dec 11, 2025	19.63	19.95	19.02	19.07	1.35M
Dec 10, 2025	20.07	20.07	19.02	19.61	1.96M

Contact Details

San Francisco, CA 94158

United States

https://www.nurixtx.com 415 660 5320

About Company

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

Stock Peers

REGN

-4.46-0.56%

Regeneron Pharmaceuticals, Inc.$796.55 ARGX

-7.07997-0.89%

argenx SE$788.49 MDGL

-42.16-7.58%

Madrigal Pharmaceuticals, Inc.$514.06 UTHR

-7.6-1.55%

United Therapeutics Corporation$483.23 VRTX

-5.82-1.24%

Vertex Pharmaceuticals Incorporated$463.86 ALNY

-1.11-0.28%

Alnylam Pharmaceuticals, Inc.$398.29 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-5.93-2.01%

Praxis Precision Medicines, Inc.$288.45 KRYS

12.5+5.02%

Krystal Biotech, Inc.$261.41 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Frequently Asked Questions

What is the current Nurix Therapeutics, Inc. (NRIX) stock price?

Nurix Therapeutics, Inc. (NASDAQ: NRIX) stock price is $19.30 in the last trading session. During the trading session, NRIX stock reached the peak price of $19.31 while $18.64 was the lowest point it dropped to. The percentage change in NRIX stock occurred in the recent session was 3.6% while the dollar amount for the price change in NRIX stock was $0.67.

NRIX's industry and sector of operation?

The NASDAQ listed NRIX is part of Biotechnology industry that operates in the broader Healthcare sector. Nurix Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of NRIX?

Mr. Howard A. Simon J.D., Esq., SPHR
Vice President of Operations & Corporation Counsel
Dr. Christine Ring
Gen. Counsel & Sec.
Rita Kwong
Senior Accounting Mang.
Mr. Howard A. Simon Esq., J.D., SPHR
Vice President of Operations & Corporation Counsel
Ms. Stefani A. Wolff
Chief Operating Officer & Executive Vice President of Product Devel.
Dr. Gwenn M. Hansen Ph.D.
Chief Scientific Officer
Dr. Arthur T. Sands M.D., Ph.D.
Chief Executive Officer, Pres & Director
Mr. Johannes Van Houte
Chief Financial Officer
Dr. John Kuriyan Ph.D.
Founder & Member of Scientific Advisory Board
Dr. Michael Rapé Ph.D.
Founder & Member of Scientific Advisory Board
Prof. Arthur Weiss M.D., Ph.D.
Founder & Member of Scientific Advisory Board
Mr. Eric C. Schlezinger J.D.
Chief People Officer
Dr. Arthur Weiss M.D., Ph.D.
Founder & Member of Scientific Advisory Board
Dr. Michael T. Lotze F.A.C.S., M.D.
Chief Cellular Therapy Officer
Dr. Christine Ring J.D., Ph.D.
Gen. Counsel & Sec.
Dr. Jason Kantor Ph.D.
Executive Vice President of Fin. & Bus. Strategy

How NRIX did perform over past 52-week?

NRIX's closing price is 135.94% higher than its 52-week low of $8.18 where as its distance from 52-week high of $22.50 is -14.22%.

How many employees does NRIX have?

Number of NRIX employees currently stands at 286.

Link for NRIX official website?

Official Website of NRIX is: https://www.nurixtx.com

How do I contact NRIX?

NRIX could be contacted at phone 415 660 5320 and can also be accessed through its website. NRIX operates from 1700 Owens Street, San Francisco, CA 94158, United States.

How many shares of NRIX are traded daily?

NRIX stock volume for the day was 1.42M shares. The average number of NRIX shares traded daily for last 3 months was 1.79M.

What is the market cap of NRIX currently?

The market value of NRIX currently stands at $1.48B with its latest stock price at $19.30 and 76.88M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	286
Beta	1.94
Sales or Revenue	$54.55M
5Y Sales Change%	-0.391%
Fiscal Year Ends	November
Sector	Healthcare
Industry	Biotechnology

Employees	286
Beta	1.94
Sales or Revenue	$54.55M
5Y Sales Change%	-0.391%
Fiscal Year Ends	November
Sector	Healthcare
Industry	Biotechnology

NRIX Company Profile and Key Details

Nurix Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Earnings & Analyst Outlook

Dividend & Fair Value

Valuation Metrics

Key Takeaways

Price Forecast & Outlook